Vitamin B12 Therapy
For vitamin B12 deficiency with neurological involvement, administer hydroxocobalamin 1 mg intramuscularly on alternate days until no further improvement occurs, then 1 mg IM every 2 months for life; for deficiency without neurological involvement, give hydroxocobalamin 1 mg IM three times weekly for 2 weeks, followed by 1 mg IM every 2-3 months lifelong. 1
Critical First Step: Assess for Neurological Involvement
Before initiating therapy, determine whether neurological symptoms are present. This distinction fundamentally changes the treatment regimen and urgency:
Neurological symptoms to assess:
- Unexplained sensory disturbances
- Motor dysfunction
- Gait abnormalities
- Cognitive changes
If any neurological involvement is suspected, seek urgent specialist advice from both a neurologist and haematologist immediately 1.
Treatment Algorithm Based on Clinical Presentation
With Neurological Involvement (Urgent)
Loading phase:
- Hydroxocobalamin 1 mg IM on alternate days until no further clinical improvement 1
Maintenance phase:
- Hydroxocobalamin 1 mg IM every 2 months for life 1
Without Neurological Involvement
Loading phase:
- Hydroxocobalamin 1 mg IM three times per week for 2 weeks 1
Maintenance phase:
- Hydroxocobalamin 1 mg IM every 2-3 months for life 1
Route of Administration
Intramuscular (IM) route is strongly preferred for B12 deficiency due to malabsorption, which is the most common etiology 2, 3. The FDA label explicitly states to avoid the intravenous route as almost all vitamin will be lost in urine 2.
While recent research suggests oral supplementation (300-1000 mcg daily) or sublingual routes may be therapeutically equivalent in some cases 4, 5, 6, parenteral therapy remains the gold standard for malabsorption-related deficiency and when neurological complications are present or suspected 3. The guideline evidence consistently recommends IM administration as first-line therapy [1-1].
Dosing Rationale
The 1 mg (1000 mcg) dose is recommended over lower doses (100 mcg) because significantly greater amounts of vitamin are retained with the higher dose, with no disadvantage in cost or toxicity 4. The FDA label supports using 100 mcg for pernicious anemia 2, but contemporary practice and guidelines favor 1 mg dosing [1-1].
Critical Safety Considerations
Never administer folic acid before treating B12 deficiency. Folic acid can mask the hematologic manifestations of B12 deficiency while allowing irreversible neurological damage (subacute combined degeneration of the spinal cord) to progress 1, 2. If both deficiencies are present, treat B12 first, then add folic acid 5 mg orally daily for minimum 4 months 1.
Vitamin B12 deficiency allowed to progress beyond 3 months may produce permanent degenerative spinal cord lesions 2. This underscores the importance of immediate treatment when deficiency is identified.
Monitoring During Initial Treatment
For the first 48 hours of treatment, monitor serum potassium closely and replace if necessary 2. During days 5-7 of therapy, check:
- Hematocrit daily
- Reticulocyte count daily
- Continue frequent monitoring until hematocrit normalizes 2
Special Populations
Pernicious anemia patients: Require lifelong monthly injections. Failure to maintain therapy will result in anemia recurrence and irreversible nerve damage 2.
Pregnancy and lactation: B12 requirements increase. Deficiency has been documented in breastfed infants of vegetarian mothers even when mothers were asymptomatic 2.
Patients on certain medications: Antibiotics, methotrexate, colchicine, para-aminosalicylic acid, and heavy alcohol use can interfere with B12 absorption 2.
Individualized Maintenance Therapy
While guidelines recommend every 2-3 month maintenance dosing, clinical experience suggests up to 50% of patients require more frequent administration (ranging from twice weekly to every 2-4 weeks) to remain symptom-free 3. Do not titrate injection frequency based on serum B12 or MMA levels—base adjustments on clinical symptom resolution and quality of life 3.